Niue Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Niue Health Report.

Press releases published on July 1, 2026

Jul. 1, 2026

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

Indeterminate GlobeNewswire

Jul. 1, 2026

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Indeterminate GlobeNewswire

Jul. 1, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Jul. 1, 2026

Stay Cool, Calm, and Collected - The AKC Offers Tips on Helping Your Dog Beat the Summer Heat

Indeterminate GlobeNewswire

Jul. 1, 2026

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients

Indeterminate GlobeNewswire

Jul. 1, 2026

Safe Legal Steroid Alternatives: CrazyBulk Announces 2026 Legal Steroids For Muscle Growth and Strength Available In USA

Indeterminate GlobeNewswire

Jul. 1, 2026

Applied Biologics Announces Expanded Strategic Focus on Surgical Applications of XWRAP®

Indeterminate GlobeNewswire

Jul. 1, 2026

Cosmos Health Completes Initial Repurchase of 2.65 Million Shares for $500,000; Continues Open Market Buybacks at Current Pace

Indeterminate GlobeNewswire

Jul. 1, 2026

Lab Automation Market Size Expected to Reach USD 8.62 Billion by 2031 | MarketsandMarkets™

Indeterminate GlobeNewswire

Jul. 1, 2026

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

Indeterminate GlobeNewswire

Jul. 1, 2026

ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs

Indeterminate GlobeNewswire

Jul. 1, 2026

Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Indeterminate GlobeNewswire

Jul. 1, 2026

Correction: Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares

Indeterminate GlobeNewswire

Jul. 1, 2026

Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29

Indeterminate GlobeNewswire

Jul. 1, 2026

Creative Medical Technology Holdings Issues Mid-Year Update

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba has received marketing authorization in France for its biofungicide AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba obtient l’autorisation de mise sur le marché en France pour son biofongicide AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba obtém autorização de colocação no mercado em França para o seu biofungicida AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba ottiene l’autorizzazione all'immissione in commercio in Francia per il suo biofungicida AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Indeterminate GlobeNewswire